Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,313 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT07004361Recruiting
Ethics of gene therapy for wet AMD
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Nantes, NantesAges 18 years+ - NCT07003386RecruitingPhase 2/Phase 3
Galantamine for recent ischemic stroke
This trial tests a plant-based medicine called galantamine, given within 3 days of an ischemic stroke, to see if it helps recovery. It combines Western and Traditional Chinese Medicine approaches and aims to understand how the treatment works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07011342Recruiting
Testing a new PET scan after focal treatment for prostate cancer
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
Hackensack, New JerseyAges 18 years+ - NCT07003646Recruiting
Treating acute pulmonary embolism with clot-dissolving or catheter procedures
This study looks at how well different treatments work for a blood clot in the lung (pulmonary embolism). It includes people who are getting or have already gotten a clot-dissolving medicine or a catheter procedure to remove the clot.
AarhusAges 18 years+ - NCT07003763Recruiting
Electroacupuncture for depression in cancer patients
This trial tests whether electroacupuncture can help treat depression caused by cancer or its treatments. It may be a safe option for people who have not tried acupuncture before and are not currently receiving active cancer treatments.
ShanghaiAges 18–75 - NCT07008638RecruitingPhase 1/Phase 2
Study of bortezomib plus CPX-351 for newly diagnosed TP53-mutated AML
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT07010237RecruitingPhase 2
Lower-dose immune therapy plus hetrombopag for older adults with severe aplastic anemia
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Tianjin, Tianjin MunicipalityAges 65 years+ - NCT07009886Recruiting
Decision aid for advanced cancer patients considering more treatment
This study is testing a tool called TA-DA to help patients with advanced cancer and their caregivers make decisions about further treatment after at least two prior therapies. It aims to improve shared decision-making.
Houston, TexasAges 18 years+ - NCT07007052RecruitingPhase 2
Tagraxofusp plus venetoclax for newly diagnosed BPDCN
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
AmiensAges 18 years+ - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07007143RecruitingPhase 4
Blood thinner study after heart valve repair
This trial tests different blood-thinning medicines after a mitral valve repair procedure (TEER) in people who do not need long-term blood thinners. It aims to find the safest and most effective strategy to prevent blood clots.
Beijing, Beijing MunicipalityAges Any age - NCT06831175RecruitingPhase 2
PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Chengdu, SichuanAges 18–70 - NCT07002684Recruiting
Esketamine study for depression
This trial tests how treatment with esketamine affects metabolism in people with depression. It may help if you have not responded to at least two standard antidepressants.
ZagrebAges 18–70 - NCT04561661Recruiting
Pinning versus splinting for finger fractures
This study compares two ways to treat certain finger bone fractures: using a small pin through the skin or using a splint. It also looks at early movement to help prevent stiffness and improve hand function.
StockholmAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT05921305RecruitingPhase 3
Low-dose methotrexate plus steroid for early acute GVHD
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Beijing, Beijing MunicipalityAges 15–65 - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06995729RecruitingPhase 1
Testing zavegepant nasal spray in children with migraines
This trial tests whether the medicine zavegepant (given as a nasal spray) is safe and works well for children aged 6 to 11 who have a history of migraines. If your child gets migraines, this study may help find a new treatment option.
Washington D.C., District of ColumbiaAges 6–11 - NCT06998680Recruiting
Chinese herbs for hair loss and gray hair
This trial tests if Chinese herbal treatments can reduce hair loss and reverse gray hair over 6 months. It may help adults who have thinning hair or graying, as long as they haven't dyed or permed their hair recently.
Xiangtan, HunanAges 18–60 - NCT06880354RecruitingPhase 1
Dual-target CAR-T cells for relapsed or refractory AML
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
TianjinAges 18–70 - NCT06846489RecruitingPhase 2
Acalabrutinib plus rituximab for untreated mantle cell lymphoma
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT06999941Enrolling by invitation
Study of deucravacitinib for psoriasis with eczema features
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
Shanghai, Shanghai MunicipalityAges 18–65
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,313 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.